Recent clinical trial data also demonstrated the utility of microsatellite instability (MSI) status as a predictive marker for response to PD-1 blockade in CRC patients treated with a checkpoint inhibitor pembrolizumab [53]. Here, PDCD1 is linked to colorectal carcinoma.